A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%. The drug wholesaler formerly known as AmerisourceBergen logged earnings of ...

"We’re creating a completely new kind of facility to seek out better, more efficient ways to manufacture new medicines, to ...

Eli Lilly and Company became the first tenant to move into Lebanon’s LEAP district during a groundbreaking ceremony on ...

Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of ...